Quoin Pharmaceuticals Ltd DRC (QNRX)vsVertex Pharmaceuticals Inc (VRTX)
QNRX
Quoin Pharmaceuticals Ltd DRC
$8.00
-1.96%
HEALTHCARE · Cap: $13.19M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
QNRX
Avoid25
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for QNRX.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : QNRX
QNRX has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : QNRX
The primary concerns for QNRX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
QNRX profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
QNRX carries more volatility with a beta of 1.82 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 25/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Quoin Pharmaceuticals Ltd DRC
HEALTHCARE · BIOTECHNOLOGY · USA
Quoin Pharmaceuticals Ltd (QNRX) is a biotechnology firm focused on developing innovative therapeutics for rare diseases and unmet medical needs. Utilizing advanced drug delivery technologies, the company enhances the efficacy and safety of established compounds, solidifying its position within the specialty pharmaceuticals sector. Quoin's robust pipeline includes therapies aimed at critical conditions, paving the way for potential clinical advancements and market opportunities. As the company progresses through its clinical trials, it remains dedicated to fostering value for both patients and shareholders through strategic collaborations and cutting-edge research initiatives.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?